¹éÇ÷±¸ Á¦°Å ±â±â ½ÃÀå : Àåºñ À¯Çüº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° - ±Ô¸ð, Á¡À¯À², Àü¸Á, ±âȸ ºÐ¼®(2023-2030³â)
Leukapheresis Devices Market, By Device Type, By Application, By End User, By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
»óǰÄÚµå : 1349985
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2023³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,354,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,884,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,120,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ¹éÇ÷±¸ Á¦°Å ±â±â ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 2,990¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, ¿¹Ãø ±â°£(2023-2030³â) CAGRÀº 7.9%·Î ¿¹ÃøµË´Ï´Ù.

¸®Æ÷Æ® ¹üÀ§ ¸®Æ÷Æ® »ó¼¼
±âÁسâ 2022 2023³â ½ÃÀå ±Ô¸ð 2,990¸¸ ´Þ·¯
°ú°Å µ¥ÀÌÅÍ 2018-2021³â ¿¹Ãø ±â°£ 2023-2030
¿¹Ãø ±â°£ 2023-2030³â CAGR : 7.90% 2030³â °¡Ä¡ ¿¹Ãø 5,100¸¸ ´Þ·¯
Leukapheresis Devices Market-IMG1

¹éÇ÷º´Àº Ç÷¾× »ùÇÿ¡¼­ ¹éÇ÷±¸¸¦ ºÐ¸®ÇÏ´Â ÀÇ·á ½Ã¼úÀÔ´Ï´Ù. ÀÌ ÀýÂ÷´Â Ç÷¾× ÇÐÀû ¾Ç¼º Á¾¾ç ȯÀÚÀÇ ¹éÇ÷±¸ ¾çÀ» ÁÙÀ̱â À§ÇØ ¼öÇàµË´Ï´Ù. µû¶ó¼­ ¹éÇ÷±¸ Á¦°Å ±â±â´ÂÀÌ ÀýÂ÷¸¦ ¿ëÀÌÇϰÔÇϱâ À§ÇØ »ç¿ëµÇ´Â ÀÇ·á±â±âÀÔ´Ï´Ù. ÀÓ»ó ¿¬±¸¿¡¼­ ¹éÇ÷±¸ °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇÏ´Â °ÍÀº ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ±â¼ú Çõ½Å°ú ¹ßÀü Áõ°¡¿Í ÇÔ²² ÇåÇ÷°ú °ü·ÃµÈ Ȱµ¿ÀÇ ¼ö°¡ Áõ°¡ÇÏ´Â °Íµµ ½ÃÀå ¼ºÀåÀÇ °áÁ¤ÀûÀÎ ¿äÀÎÀÔ´Ï´Ù. °³ÀÎÀÇ °Ç°­ ÀÎ½Ä Áõ°¡, ¹éÇ÷±¸(WBC) ºÐ¸® °úÁ¤¿¡ ´ëÇÑ ½ÂÀÎ Áõ°¡, ÀÇ·á °ü±¤ Áõ°¡´Â À¯¸®ÇÑ ½ÃÀå ¼ºÀå ±âȸ¸¦ âÃâÇÏ´Â ¶Ç ´Ù¸¥ Áß¿äÇÑ ¿äÀÎÀÔ´Ï´Ù.

½ÃÀå ¿ªÇÐ

ÀÌ ¼¼°è ¹éÇ÷±¸ Á¦°Å ±â±â ½ÃÀå º¸°í¼­´Â ÃÖ±Ù µ¿Çâ, ¹«¿ª ±ÔÁ¦, ¼öÃâÀÔ ºÐ¼®, »ý»ê ºÐ¼®, ¹ë·ùüÀÎ ÃÖÀûÈ­, ½ÃÀå Á¡À¯À², ±¹³» ¹× ÇöÁöÈ­µÈ ½ÃÀå ±â¾÷ÀÇ ¿µÇâ, »õ·Î¿î ¼öÀÔ¿ø, ½ÃÀå ±ÔÁ¦ º¯È­, Àü·«Àû ½ÃÀå ¼ºÀå ºÐ¼®, ½ÃÀå ±Ô¸ð, Ä«Å×°í¸® ½ÃÀå ¼ºÀå, ¿ëµµ Æ´»õ ¹× ¿ìÀ§, Á¦Ç° ½ÂÀÎ, Á¦Ç° Ãâ½Ã, Áö¿ªº° ½ÃÀå ºÐ¼®, ½ÃÀå³» ±â¼ú Çõ½Å¿¡ ´ëÇÑ ¼¼ºÎ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 12¿ù, ExThera MedicalÀº Ç÷·ù °¨¿° Ä¡·áÀÇ ¹ÌÃæÁ· ÀÓ»ó ¼ö¿ä¸¦ ÃæÁ·½ÃŰ´Â ȹ±âÀûÀÎ ÀÇ·á±â±â¸¦ °³¹ßÇϰí ÀÖÀ¸¸ç, ¾Æ»çÈ÷Ä«¼¼ÀÌ ±×·ìÀÇ ÇÙ½É »ç¾÷ ȸ»çÀÎ Asahi Kasei Medical Co. Seraph 100 Microbind Affinity Blood Filter(Seraph 100)ÀÇ ÀϺ»³» µ¶Á¡ ÆÇ¸Å °è¾àÀ» ü°áÇß½À´Ï´Ù. À̹ø °è¾à¿¡ µû¶ó ExThera Medical°ú Asahi Kasei Medical Co. Ltd.´Â Seraph 100ÀÇ ÀϺ»³» ÆÇ¸Å ½ÂÀÎÀ» ¹Þ±â À§ÇØ Çù·ÂÇÒ ¿¹Á¤ÀÔ´Ï´Ù. ¹éÇ÷º´ÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ ¼¼°è ¹éÇ÷±¸ Á¦°Å ±â±â ½ÃÀåÀº ¿¹Ãø ±â°£ Áß Å« ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 6¿ù, ÅÚ¸ð ºí·¯µå´Â Ç÷¾× ¼ººÐ, Ä¡·á¿ë ¾îÆç·¹½Ã½º ¹× ¼¼Æ÷ ±â¼ú ºÐ¾ß¿¡¼­ ¼¿Å×Å©³î·¯Áö½º´Â Ç÷¾× ¼ººÐ äÃë, Ä¡·á¿ë ¾îÆç·¹½Ã½º ¹× ¼¼Æ÷ ±â¼úÀ» À§ÇÑ Á¦Ç°, ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º Æ÷Æ®Æú¸®¿À¸¦ Àü¹®À¸·Î ÇÏ´Â ÀÇ·á ±â¼ú ±â¾÷À̸ç, ¹ÙÀÌ¿Àºê¸´Áö ¿ùµå(BioBridge World)ÀÇ ÀÚȸ»çÀÎ GenCure¿Í ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á Á¦Á¶ ¼Ö·ç¼ÇÀÇ È®Àå ¹× ÅëÇÕÀ» À§ÇÑ »õ·Î¿î Çù·Â °è¾àÀ» ü°áÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå °³¿ä

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ ¹éÇ÷±¸ Á¦°Å ±â±â ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦5Àå ¼¼°èÀÇ ¹éÇ÷±¸ Á¦°Å ±â±â ½ÃÀå : Àåºñ À¯Çüº°, 2018-2030³â

Á¦6Àå ¼¼°èÀÇ ¹éÇ÷±¸ Á¦°Å ±â±â ½ÃÀå : ¿ëµµº°, 2018-2030³â

Á¦7Àå ¼¼°èÀÇ ¹éÇ÷±¸ Á¦°Å ±â±â ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°, 2018-2030³â

Á¦8Àå ¼¼°èÀÇ ¹éÇ÷±¸ Á¦°Å ±â±â ½ÃÀå : Áö¿ªº°, 2018-2030³â

Á¦9Àå ±â¾÷ °³¿ä

Á¦10Àå ¼½¼Ç

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global leukapheresis devices market is estimated to be valued at US$ 29.9 Million in 2023 and is expected to exhibit a CAGR of 7.9% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 29.9 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 7.90% 2030 Value Projection: US$ 51 Mn
Leukapheresis Devices Market - IMG1

Leukaemia is a medical procedure that involves separating white blood cells from a sample of blood. The procedure is undergone to reduce the quantity of white blood cells in patients wuth hematological malignancies. Therefore, leukapheresis devices are the medical devices that are used to facilitate this procedure. The surge in demand for leukopaks in clinical research is one of the major factors fostering the growth of the market. Growth in the number of activities associated with blood donations coupled with growing innovations and advancements in technologies is another market growth determinant. Rising health awareness among individuals, growing approvals for processes of isolating white blood cells (WBC), and rising medical tourism are other important factors that will further generate lucrative market growth opportunities.

Market Dynamics

This global leukapheresis devices market report provides details of recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, and technological innovations in the market. For instance, In December 2021, ExThera Medical develops revolutionary medical devices that address unmet clinical needs in the treatment of bloodstream infections and Asahi Kasei Medical, a core operating company of the Asahi Kasei Group, entered into an exclusive distribution agreement in Japan for ExThera's Seraph 100 Microbind Affinity Blood Filter (Seraph 100). As per the agreement structure, ExThera Medical and Asahi Kasei Medical will collaborate to obtain regulatory approval for Seraph 100 for commercialization in Japan. The global leukapheresis devices market is expected to witness significant growth during the forecast period, owing to the increasing prevalence of leukemia. For instance, in June 2022, Terumo Blood is in blood component, therapeutic apheresis and cellular technologies and Cell Technologies, a medical technology company specializing in a portfolio of products, software, and services for blood component collection, therapeutic apheresis, and cellular technologies, announced it had signed a new collaborative agreement with GenCure, a subsidiary of BioBridge Global, to extend and unify cell and gene therapy manufacturing solutions.

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Leukapheresis Devices Market- COVID-19 Impact Analysis

5. Global Leukapheresis Devices Market, By Device Type, 2018-2030, (US$ Mn)

6. Global Leukapheresis Devices Market, By Application, 2018-2030, (US$ Mn)

7. Global Leukapheresis Devices Market, By End User, 2018-2030, (US$ Mn)

8. Global Leukapheresis Devices Market, By Region, 2018-2030, (US$ Mn)

9. Company Profiles

10. Section

About us and Sales Contact*Browse 36 market data tables and 33 figures on "Leukapheresis Devices Market "- Global Forecast to 2030

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â